A Study of Sovilnesib in Subjects With Ovarian Cancer
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics
(PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase
2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).